This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Pediatr Adolesc Med. 2001;155:1176-1178.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

I read with great interest the article by Lobaugh et al¹ in the April 2001 issue of the ARCHIVES. I recently published 2 original articles on aberrations in intermediary metabolism and the effects of a peptide therapy on partially trisomic Ts65Dn mice, an animal model for Down syndrome. I am familiar with the claims of various Down syndrome advocacy groups on the use of the drug piracetam and with various nutritional intervention strategies to address health issues associated with this genetic disorder. Finally, I was also interviewed and quoted in 2 of the 3 American Broadcasting Corporation programs in which piracetam was discussed.

I am greatly concerned about how the data in this article were analyzed, interpreted, and discussed. First, from the most fundamental standpoint, the authors did not truly test the efficacy of piracetam as presented in anecdotal accounts and they did not test the drug against a background . . . [Full Text of this Article]